Share This Author
Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study.
Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer.
Safety and Efficacy of Medical Cannabis in Fibromyalgia
- I. Sagy, Lihi Bar-Lev Schleider, M. Abu-Shakra, V. Novack
- MedicineJournal of clinical medicine
- 1 June 2019
Medical cannabis appears to be a safe and effective alternative for the treatment of fibromyalgia symptoms and standardization of treatment compounds and regimens are required.
Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience
Medical cannabis was found to improve symptoms of PD in the initial stages of treatment and did not cause major adverse effects in this pilot, 2-center, retrospective survey.
Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy
- Lihi Bar-Lev Schleider, R. Mechoulam, N. Saban, G. Meiri, V. Novack
- Medicine, PsychologyScientific Reports
- 17 January 2019
Cannabis in ASD patients appears to be well tolerated, safe and effective option to relieve symptoms associated with ASD and its safety and efficacy is described.
Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects.
- T. Naftali, Lihi Bar-Lev Schleider, F. Sklerovsky Benjaminov, I. Lish, F. Konikoff, Y. Ringel
- MedicineEuropean journal of gastroenterology & hepatology
- 1 November 2019
Cannabis use by inflammatory bowel disease patients can induce clinical improvement and is associated with reduced use of medication and slight weight gain, and most patients respond well to a dose of 30 g/month, or 21 mg Δ9-tetra- hydrocannabinol and 170 mg Cannabidiol (CBD) per day.
Medical cannabis: aligning use to evidence‐based medicine approach
- Lihi Bar-Lev Schleider, Ran Abuhasira, V. Novack
- MedicineBritish journal of clinical pharmacology
- 28 August 2018
Israel has created a medical and regulatory environment that enables clinical studies with cannabis which may lead to improved Evidence Based use of these compounds.
Oral CBD-rich cannabis induces clinical but not endoscopic response in patients with Crohn's disease, a randomized controlled trial.
- T. Naftali, Lihi Bar-Lev Schleider, S. Almog, D. Meiri, F. Konikoff
- MedicineJournal of Crohn's & colitis
- 15 April 2021
Until further studies are available, cannabis treatment in Crohn's disease should be used only in the context of clinical trials.
Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial.
- T. Naftali, Lihi Bar-Lev Schleider, Fabiana Scklerovsky Benjaminov, F. Konikoff, S. Matalon, Y. Ringel
- MedicinePloS one
- 11 February 2021
Short term treatment with THC rich cannabis induced clinical remission and improved quality of life in patients with mild to moderately active ulcerative colitis, however, these beneficial clinical effects were not associated with significant anti-inflammatory improvement in the Mayo endoscopic score or laboratory markers for inflammation.
Adherence, Safety, and Effectiveness of Medical Cannabis and Epidemiological Characteristics of the Patient Population: A Prospective Study
- Lihi Bar-Lev Schleider, R. Mechoulam, Inbal Sikorin, T. Naftali, V. Novack
- Medicine, PsychologyFrontiers in Medicine
- 9 February 2022
It is observed that supervised medical-cannabis treatment is associated with high adherence, improvement in quality of life, and a decrease in pain level with a low incidence of serious adverse events.